Please assess the completion status of the following clinical trial:

Trial Title: Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Must be 18 to 75 years of age.~* ECOG performance status of 0, 1 or 2.~* Patients who have a history of another malignant disorder are eligible, provided that they have not received active therapy for 5 years. Patients with basal cell and squamous cell skin cancers are eligible.~* Patients who are pregnant are ineligible.~* Patients must furnish written informed consent and HIPAA authorization for release of personal health information.~* Patients must be able to understand the requirements of the study, abide by the study restrictions, and agree to return for the required assessments.~* Patients must be HIV and HTLV-I,-II antibody sero-negative.~* Patients must have adequate visceral organ function~Exclusion Criteria:~* Patients are ineligible if they have received cumulative chemotherapy doses in excess of: carmustine (BCNU) 400 mg/m2, or a cumulative anthracycline exposure in excess of 550 mg/m2 Adriamycin (doxorubicin) unless the gated-pool radionuclide cardiac scan shows greater than/equal to 45% ejection fraction.~* Patients are ineligible if they are receiving any other investigational agents.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Maintenance Lenalidomide After Melphalan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).